- Home
- KRC vs TVTX Comparison
KRC vs TVTX Comparison
Compare KRC & TVTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | KRC | TVTX |
|---|---|---|
| Founded | 1947 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.4B | 4.7B |
| IPO Year | 1996 | 2013 |
Fundamental Metrics
Financial Performance| Metric | KRC | TVTX |
|---|---|---|
| Price | $36.07 | $50.74 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 17 | 15 |
| Target Price | $39.71 | ★ $73.43 |
| AVG Volume (30 Days) | 1.4M | ★ 2.1M |
| Earning Date | 10-22-2026 | 11-02-2026 |
| Dividend Yield | ★ 6.03% | N/A |
| EPS Growth | 31.07 | ★ 92.89 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,112,667,000.00 | N/A |
| Revenue This Year | N/A | $55.96 |
| Revenue Next Year | $2.32 | $48.63 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $27.36 | $22.59 |
| 52 Week High | $43.58 | $68.73 |
Technical Indicators
Market Signals| Indicator | KRC | TVTX |
|---|---|---|
| Relative Strength Index (RSI) | 51.63 | 44.19 |
| Support Level | $35.88 | $49.46 |
| Resistance Level | $37.75 | $54.43 |
| Average True Range (ATR) | 0.96 | 2.61 |
| MACD | -0.06 | 0.49 |
| Stochastic Oscillator | 26.73 | 70.30 |
Price Performance
Historical ComparisonAbout KRC Kilroy Realty Corporation
Kilroy Realty is a premier owner and landlord of approximately 16.3 million square feet of office space across Los Angeles, San Diego, the San Francisco Bay Area, Austin, Texas, and greater Seattle. The company operates as a real estate investment trust.
About TVTX Travere Therapeutics Inc.
Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN)-rare kidney disorders that often cause end-stage kidney disease. It is also advancing pegtibatinase, a novel investigational enzyme replacement therapy for the treatment of HCU, a genetic disorder caused by a deficiency in a pivotal enzyme essential to the body.